FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact
Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:DRD2-DRD2 (FusionGDB2 ID:24137)

Fusion Gene Summary for DRD2-DRD2

check button Fusion gene summary
Fusion gene informationFusion gene name: DRD2-DRD2
Fusion gene ID: 24137
HgeneTgene
Gene symbol

DRD2

DRD2

Gene ID

1813

1813

Gene namedopamine receptor D2dopamine receptor D2
SynonymsD2DR|D2RD2DR|D2R
Cytomap

11q23.2

11q23.2

Type of geneprotein-codingprotein-coding
DescriptionD(2) dopamine receptordopamine D2 receptordopamine receptor D2 isoformseven transmembrane helix receptorD(2) dopamine receptordopamine D2 receptordopamine receptor D2 isoformseven transmembrane helix receptor
Modification date2020032220200322
UniProtAcc.

P14416

Ensembl transtripts involved in fusion geneENST00000355319, ENST00000346454, 
ENST00000362072, ENST00000544518, 
ENST00000542968, ENST00000538967, 
ENST00000535984, 		ENST00000355319, 
ENST00000346454, ENST00000362072, 
ENST00000544518, ENST00000542968, 
ENST00000538967, ENST00000535984, 
Fusion gene scores* DoF score1 X 1 X 1=12 X 3 X 2=12
# samples 12
** MAII scorelog2(1/1*10)=3.32192809488736log2(2/12*10)=0.736965594166206
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Context

PubMed: DRD2 [Title/Abstract] AND DRD2 [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointDRD2(113282109)-DRD2(113281573), # samples:1
Anticipated loss of major functional domain due to fusion event.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneDRD2

GO:0007195

adenylate cyclase-inhibiting dopamine receptor signaling pathway

8666994|26554819

HgeneDRD2

GO:0034776

response to histamine

16839358

HgeneDRD2

GO:0050482

arachidonic acid secretion

8301582

HgeneDRD2

GO:0050709

negative regulation of protein secretion

16839358

HgeneDRD2

GO:1900168

positive regulation of glial cell-derived neurotrophic factor secretion

23373701

TgeneDRD2

GO:0007195

adenylate cyclase-inhibiting dopamine receptor signaling pathway

8666994|26554819

TgeneDRD2

GO:0034776

response to histamine

16839358

TgeneDRD2

GO:0050482

arachidonic acid secretion

8301582

TgeneDRD2

GO:0050709

negative regulation of protein secretion

16839358

TgeneDRD2

GO:1900168

positive regulation of glial cell-derived neurotrophic factor secretion

23373701


check buttonFusion gene breakpoints across DRD2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check buttonFusion gene breakpoints across DRD2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

check button Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChiTaRS5.0N/ABE835045DRD2chr11

113282109

+DRD2chr11

113281573

-


Top

Fusion Gene ORF analysis for DRD2-DRD2

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
intron-3CDSENST00000355319ENST00000355319DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000355319ENST00000346454DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000355319ENST00000362072DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000355319ENST00000544518DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000355319ENST00000542968DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000355319ENST00000538967DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-intronENST00000355319ENST00000535984DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000346454ENST00000355319DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000346454ENST00000346454DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000346454ENST00000362072DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000346454ENST00000544518DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000346454ENST00000542968DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000346454ENST00000538967DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-intronENST00000346454ENST00000535984DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000362072ENST00000355319DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000362072ENST00000346454DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000362072ENST00000362072DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000362072ENST00000544518DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000362072ENST00000542968DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000362072ENST00000538967DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-intronENST00000362072ENST00000535984DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000544518ENST00000355319DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000544518ENST00000346454DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000544518ENST00000362072DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000544518ENST00000544518DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000544518ENST00000542968DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000544518ENST00000538967DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-intronENST00000544518ENST00000535984DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000542968ENST00000355319DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000542968ENST00000346454DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000542968ENST00000362072DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000542968ENST00000544518DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000542968ENST00000542968DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000542968ENST00000538967DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-intronENST00000542968ENST00000535984DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000538967ENST00000355319DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000538967ENST00000346454DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000538967ENST00000362072DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000538967ENST00000544518DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000538967ENST00000542968DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000538967ENST00000538967DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-intronENST00000538967ENST00000535984DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000535984ENST00000355319DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000535984ENST00000346454DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000535984ENST00000362072DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000535984ENST00000544518DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000535984ENST00000542968DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-3CDSENST00000535984ENST00000538967DRD2chr11

113282109

+DRD2chr11

113281573

-
intron-intronENST00000535984ENST00000535984DRD2chr11

113282109

+DRD2chr11

113281573

-

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score

Top

Fusion Genomic Features for DRD2-DRD2


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for DRD2-DRD2


check button Go to

FGviewer for the breakpoints of :-:

.
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
.DRD2

P14416

FUNCTION: Might normally function as a transcriptional repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes.FUNCTION: Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase (PubMed:21645528). Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity). {ECO:0000250|UniProtKB:P61168, ECO:0000269|PubMed:21645528}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note


Top

Fusion Gene Sequence for DRD2-DRD2


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

Top

Fusion Gene PPI Analysis for DRD2-DRD2


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for DRD2-DRD2


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status
TgeneDRD2P14416DB00246ZiprasidoneAntagonistSmall moleculeApproved
TgeneDRD2P14416DB00248CabergolineAgonistSmall moleculeApproved
TgeneDRD2P14416DB00363ClozapineAntagonistSmall moleculeApproved
TgeneDRD2P14416DB00408LoxapineAntagonistSmall moleculeApproved
TgeneDRD2P14416DB00458ImipramineBinderSmall moleculeApproved
TgeneDRD2P14416DB00502HaloperidolAntagonistSmall moleculeApproved
TgeneDRD2P14416DB00540NortriptylineAntagonistSmall moleculeApproved
TgeneDRD2P14416DB00543AmoxapineAntagonistSmall moleculeApproved
TgeneDRD2P14416DB00623FluphenazineAntagonistSmall moleculeApproved
TgeneDRD2P14416DB00696ErgotamineAgonistSmall moleculeApproved
TgeneDRD2P14416DB00726TrimipramineOther/unknownSmall moleculeApproved
TgeneDRD2P14416DB00777PropiomazineAntagonistSmall moleculeApproved
TgeneDRD2P14416DB00805MinaprineAgonistSmall moleculeApproved
TgeneDRD2P14416DB00850PerphenazineAntagonistSmall moleculeApproved
TgeneDRD2P14416DB00915AmantadineAgonistSmall moleculeApproved
TgeneDRD2P14416DB00988DopamineAgonistSmall moleculeApproved
TgeneDRD2P14416DB01063AcetophenazineAntagonistSmall moleculeApproved
TgeneDRD2P14416DB01100PimozideAntagonistSmall moleculeApproved
TgeneDRD2P14416DB01175EscitalopramInhibitorSmall moleculeApproved
TgeneDRD2P14416DB01224QuetiapineAntagonistSmall moleculeApproved
TgeneDRD2P14416DB01235LevodopaAgonistSmall moleculeApproved
TgeneDRD2P14416DB01267PaliperidoneAntagonistSmall moleculeApproved
TgeneDRD2P14416DB01618MolindoneAntagonistSmall moleculeApproved
TgeneDRD2P14416DB01623ThiothixeneAntagonistSmall moleculeApproved
TgeneDRD2P14416DB04946IloperidoneAntagonistSmall moleculeApproved
TgeneDRD2P14416DB05271RotigotineAgonistSmall moleculeApproved
TgeneDRD2P14416DB06216AsenapineAntagonistSmall moleculeApproved
TgeneDRD2P14416DB11274Dihydro-alpha-ergocryptineAgonistSmall moleculeApproved
TgeneDRD2P14416DB01239ChlorprothixeneAntagonistSmall moleculeApproved|Experimental|Investigational|Withdrawn
TgeneDRD2P14416DB00182AmphetamineBinderSmall moleculeApproved|Illicit|Investigational
TgeneDRD2P14416DB00268RopiniroleAgonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00334OlanzapineAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00391SulpirideAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00413PramipexoleAgonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00490BuspironeAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00555LamotrigineAgonist|InhibitorSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00568CinnarizineOther/unknownSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00589LisurideAgonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00714ApomorphineAgonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00715ParoxetineOther/unknownSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00734RisperidoneAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00831TrifluoperazineAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00933MesoridazineAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00934MaprotilineBinderSmall moleculeApproved|Investigational
TgeneDRD2P14416DB01043MemantineAgonist|AntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB01069PromethazineAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB01151DesipramineBinderSmall moleculeApproved|Investigational
TgeneDRD2P14416DB01200BromocriptineAgonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB01233MetoclopramideAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB01238AripiprazoleAntagonist|Partial agonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB01403MethotrimeprazineAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB01621PipotiazineAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB01624ZuclopenthixolAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB04842FluspirileneAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB04844TetrabenazineInhibitorSmall moleculeApproved|Investigational
TgeneDRD2P14416DB05316PimavanserinSmall moleculeApproved|Investigational
TgeneDRD2P14416DB06016CariprazineAgonist|Partial agonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB06077LumateperonePartial agonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB06148MianserinAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB06288AmisulprideAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB08815LurasidoneAntagonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB09097QuinagolideAgonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB09128BrexpiprazoleAgonist|Partial agonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB14185Aripiprazole lauroxilPartial agonistSmall moleculeApproved|Investigational
TgeneDRD2P14416DB00477ChlorpromazineAntagonistSmall moleculeApproved|Investigational|Vet_approved
TgeneDRD2P14416DB01184DomperidoneAntagonistSmall moleculeApproved|Investigational|Vet_approved
TgeneDRD2P14416DB01392YohimbineAntagonistSmall moleculeApproved|Investigational|Vet_approved
TgeneDRD2P14416DB01186PergolideAgonistSmall moleculeApproved|Investigational|Vet_approved|Withdrawn
TgeneDRD2P14416DB00875FlupentixolAntagonistSmall moleculeApproved|Investigational|Withdrawn
TgeneDRD2P14416DB06144SertindoleAntagonistSmall moleculeApproved|Investigational|Withdrawn
TgeneDRD2P14416DB09225ZotepineAntagonistSmall moleculeApproved|Investigational|Withdrawn
TgeneDRD2P14416DB00420PromazineAntagonistSmall moleculeApproved|Vet_approved
TgeneDRD2P14416DB00433ProchlorperazineAntagonistSmall moleculeApproved|Vet_approved
TgeneDRD2P14416DB00450DroperidolAntagonistSmall moleculeApproved|Vet_approved
TgeneDRD2P14416DB00508TriflupromazineAntagonistSmall moleculeApproved|Vet_approved
TgeneDRD2P14416DB01221KetamineAgonist|Partial agonistSmall moleculeApproved|Vet_approved
TgeneDRD2P14416DB00372ThiethylperazineAntagonistSmall moleculeApproved|Withdrawn
TgeneDRD2P14416DB00409RemoxiprideAntagonistSmall moleculeApproved|Withdrawn
TgeneDRD2P14416DB00679ThioridazineAntagonistSmall moleculeApproved|Withdrawn
TgeneDRD2P14416DB01614AcepromazineAntagonistSmall moleculeExperimental|Vet_approved

Top

Related Diseases for DRD2-DRD2


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneDRD2C0600427Cocaine Dependence15CTD_human;PSYGENET
HgeneDRD2C0009171Cocaine Abuse14CTD_human;PSYGENET
HgeneDRD2C0236736Cocaine-Related Disorders10CTD_human
HgeneDRD2C0001973Alcoholic Intoxication, Chronic5PSYGENET
HgeneDRD2C0004782Basal Ganglia Diseases5CTD_human
HgeneDRD2C0005586Bipolar Disorder5PSYGENET
HgeneDRD2C0011570Mental Depression5PSYGENET
HgeneDRD2C0011581Depressive disorder5PSYGENET
HgeneDRD2C0015371Extrapyramidal Disorders5CTD_human
HgeneDRD2C0041696Unipolar Depression5PSYGENET
HgeneDRD2C0085762Alcohol abuse5PSYGENET
HgeneDRD2C0525045Mood Disorders5PSYGENET
HgeneDRD2C0750951Lenticulostriate Disorders5CTD_human
HgeneDRD2C1269683Major Depressive Disorder5PSYGENET
HgeneDRD2C0007370Catalepsy4CTD_human
HgeneDRD2C0020649Hypotension4CTD_human
HgeneDRD2C0036341Schizophrenia4CTD_human
HgeneDRD2C0233612Waxy flexibility4CTD_human
HgeneDRD2C0013386Dyskinesia, Drug-Induced3CTD_human
HgeneDRD2C0021122Disruptive, Impulse Control, and Conduct Disorders3CTD_human
HgeneDRD2C0021776Intermittent Explosive Disorder3CTD_human
HgeneDRD2C0022333Jacksonian Seizure3CTD_human
HgeneDRD2C0036572Seizures3CTD_human
HgeneDRD2C0149958Complex partial seizures3CTD_human
HgeneDRD2C0234533Generalized seizures3CTD_human
HgeneDRD2C0234535Clonic Seizures3CTD_human
HgeneDRD2C0236733Amphetamine-Related Disorders3CTD_human
HgeneDRD2C0236804Amphetamine Addiction3CTD_human
HgeneDRD2C0236807Amphetamine Abuse3CTD_human
HgeneDRD2C0242422Parkinsonian Disorders3CTD_human
HgeneDRD2C0242423Ramsay Hunt Paralysis Syndrome3CTD_human
HgeneDRD2C0270824Visual seizure3CTD_human
HgeneDRD2C0270844Tonic Seizures3CTD_human
HgeneDRD2C0270846Epileptic drop attack3CTD_human
HgeneDRD2C0422850Seizures, Somatosensory3CTD_human
HgeneDRD2C0422852Seizures, Auditory3CTD_human
HgeneDRD2C0422853Olfactory seizure3CTD_human
HgeneDRD2C0422854Gustatory seizure3CTD_human
HgeneDRD2C0422855Vertiginous seizure3CTD_human
HgeneDRD2C0494475Tonic - clonic seizures3CTD_human
HgeneDRD2C0751056Non-epileptic convulsion3CTD_human
HgeneDRD2C0751088Dyskinesia, Medication-Induced3CTD_human
HgeneDRD2C0751110Single Seizure3CTD_human
HgeneDRD2C0751123Atonic Absence Seizures3CTD_human
HgeneDRD2C0751494Convulsive Seizures3CTD_human
HgeneDRD2C0751495Seizures, Focal3CTD_human
HgeneDRD2C0751496Seizures, Sensory3CTD_human
HgeneDRD2C0752097Autosomal Dominant Juvenile Parkinson Disease3CTD_human
HgeneDRD2C0752098Autosomal Dominant Parkinsonism3CTD_human
HgeneDRD2C0752100Autosomal Recessive Parkinsonism3CTD_human
HgeneDRD2C0752101Parkinsonism, Experimental3CTD_human
HgeneDRD2C0752104Familial Juvenile Parkinsonism3CTD_human
HgeneDRD2C0752105Parkinsonism, Juvenile3CTD_human
HgeneDRD2C1868675PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE3CTD_human
HgeneDRD2C3495874Nonepileptic Seizures3CTD_human
HgeneDRD2C4048158Convulsions3CTD_human
HgeneDRD2C4316903Absence Seizures3CTD_human
HgeneDRD2C4317109Epileptic Seizures3CTD_human
HgeneDRD2C4317123Myoclonic Seizures3CTD_human
HgeneDRD2C4505436Generalized Absence Seizures3CTD_human
HgeneDRD2C0003469Anxiety Disorders2CTD_human
HgeneDRD2C0006870Cannabis Dependence2PSYGENET
HgeneDRD2C0011206Delirium2PSYGENET
HgeneDRD2C0020514Hyperprolactinemia2CTD_human
HgeneDRD2C0024809Marijuana Abuse2PSYGENET
HgeneDRD2C0039231Tachycardia2CTD_human
HgeneDRD2C0080203Tachyarrhythmia2CTD_human
HgeneDRD2C0376280Anxiety States, Neurotic2CTD_human
HgeneDRD2C0428977Bradycardia2CTD_human
HgeneDRD2C0751217Hyperkinesia, Generalized2CTD_human
HgeneDRD2C1279420Anxiety neurosis (finding)2CTD_human
HgeneDRD2C3887506Hyperkinesia2CTD_human
HgeneDRD2C0008073Developmental Disabilities1CTD_human
HgeneDRD2C0009241Cognition Disorders1CTD_human
HgeneDRD2C0013146Drug abuse1CTD_human
HgeneDRD2C0013170Drug habituation1CTD_human
HgeneDRD2C0013222Drug Use Disorders1CTD_human
HgeneDRD2C0013384Dyskinetic syndrome1CTD_human
HgeneDRD2C0019337Heroin Dependence1CTD_human
HgeneDRD2C0020538Hypertensive disease1CTD_human
HgeneDRD2C0023015Language Disorders1CTD_human
HgeneDRD2C0024517Major depression, single episode1PSYGENET
HgeneDRD2C0025261Memory Disorders1CTD_human
HgeneDRD2C0026650Movement Disorders1CTD_human
HgeneDRD2C0028043Nicotine Dependence1CTD_human
HgeneDRD2C0029231Organic Mental Disorders, Substance-Induced1CTD_human
HgeneDRD2C0030193Pain1CTD_human
HgeneDRD2C0030567Parkinson Disease1CTD_human
HgeneDRD2C0032000Pituitary Adenoma1CTD_human
HgeneDRD2C0032019Pituitary Neoplasms1CTD_human
HgeneDRD2C0038580Substance Dependence1CTD_human
HgeneDRD2C0038586Substance Use Disorders1CTD_human
HgeneDRD2C0038587Substance Withdrawal Syndrome1CTD_human
HgeneDRD2C0040332Tobacco Dependence1CTD_human
HgeneDRD2C0041671Attention Deficit Disorder1CTD_human
HgeneDRD2C0043094Weight Gain1CTD_human
HgeneDRD2C0085996Child Development Deviations1CTD_human
HgeneDRD2C0085997Child Development Disorders, Specific1CTD_human
HgeneDRD2C0086189Drug Withdrawal Symptoms1CTD_human
HgeneDRD2C0087169Withdrawal Symptoms1CTD_human
HgeneDRD2C0152115Lingual-Facial-Buccal Dyskinesia1CTD_human
HgeneDRD2C0178417Anhedonia1PSYGENET
HgeneDRD2C0221169Hemiballismus1CTD_human
HgeneDRD2C0221480Recurrent depression1PSYGENET
HgeneDRD2C0232766Asterixis1CTD_human
HgeneDRD2C0233794Memory impairment1CTD_human
HgeneDRD2C0234230Pain, Burning1CTD_human
HgeneDRD2C0234238Ache1CTD_human
HgeneDRD2C0234254Radiating pain1CTD_human
HgeneDRD2C0236969Substance-Related Disorders1CTD_human
HgeneDRD2C0266487Etat Marbre1CTD_human
HgeneDRD2C0346300Pituitary carcinoma1CTD_human
HgeneDRD2C0376384Nicotine Use Disorder1CTD_human
HgeneDRD2C0427086Involuntary Movements1CTD_human
HgeneDRD2C0454560Acquired Language Disorders1CTD_human
HgeneDRD2C0454606Oral Dyskinesia1CTD_human
HgeneDRD2C0458257Pain, Splitting1CTD_human
HgeneDRD2C0458259Pain, Crushing1CTD_human
HgeneDRD2C0600241heroin abuse1CTD_human
HgeneDRD2C0740858Substance abuse problem1CTD_human
HgeneDRD2C0751292Age-Related Memory Disorders1CTD_human
HgeneDRD2C0751293Memory Disorder, Semantic1CTD_human
HgeneDRD2C0751294Memory Disorder, Spatial1CTD_human
HgeneDRD2C0751295Memory Loss1CTD_human
HgeneDRD2C0751407Pain, Migratory1CTD_human
HgeneDRD2C0751408Suffering, Physical1CTD_human
HgeneDRD2C0752196Ballismus1CTD_human
HgeneDRD2C1263846Attention deficit hyperactivity disorder1CTD_human
HgeneDRD2C1321905Minimal Brain Dysfunction1CTD_human
HgeneDRD2C1510472Drug Dependence1CTD_human
HgeneDRD2C4316881Prescription Drug Abuse1CTD_human
HgeneDRD2C4505390Heroin Smoking1CTD_human
TgeneDRD2C0600427Cocaine Dependence15CTD_human;PSYGENET
TgeneDRD2C0009171Cocaine Abuse14CTD_human;PSYGENET
TgeneDRD2C0236736Cocaine-Related Disorders10CTD_human
TgeneDRD2C0001973Alcoholic Intoxication, Chronic5PSYGENET
TgeneDRD2C0004782Basal Ganglia Diseases5CTD_human
TgeneDRD2C0005586Bipolar Disorder5PSYGENET
TgeneDRD2C0011570Mental Depression5PSYGENET
TgeneDRD2C0011581Depressive disorder5PSYGENET
TgeneDRD2C0015371Extrapyramidal Disorders5CTD_human
TgeneDRD2C0041696Unipolar Depression5PSYGENET
TgeneDRD2C0085762Alcohol abuse5PSYGENET
TgeneDRD2C0525045Mood Disorders5PSYGENET
TgeneDRD2C0750951Lenticulostriate Disorders5CTD_human
TgeneDRD2C1269683Major Depressive Disorder5PSYGENET
TgeneDRD2C0007370Catalepsy4CTD_human
TgeneDRD2C0020649Hypotension4CTD_human
TgeneDRD2C0036341Schizophrenia4CTD_human
TgeneDRD2C0233612Waxy flexibility4CTD_human
TgeneDRD2C0013386Dyskinesia, Drug-Induced3CTD_human
TgeneDRD2C0021122Disruptive, Impulse Control, and Conduct Disorders3CTD_human
TgeneDRD2C0021776Intermittent Explosive Disorder3CTD_human
TgeneDRD2C0022333Jacksonian Seizure3CTD_human
TgeneDRD2C0036572Seizures3CTD_human
TgeneDRD2C0149958Complex partial seizures3CTD_human
TgeneDRD2C0234533Generalized seizures3CTD_human
TgeneDRD2C0234535Clonic Seizures3CTD_human
TgeneDRD2C0236733Amphetamine-Related Disorders3CTD_human
TgeneDRD2C0236804Amphetamine Addiction3CTD_human
TgeneDRD2C0236807Amphetamine Abuse3CTD_human
TgeneDRD2C0242422Parkinsonian Disorders3CTD_human
TgeneDRD2C0242423Ramsay Hunt Paralysis Syndrome3CTD_human
TgeneDRD2C0270824Visual seizure3CTD_human
TgeneDRD2C0270844Tonic Seizures3CTD_human
TgeneDRD2C0270846Epileptic drop attack3CTD_human
TgeneDRD2C0422850Seizures, Somatosensory3CTD_human
TgeneDRD2C0422852Seizures, Auditory3CTD_human
TgeneDRD2C0422853Olfactory seizure3CTD_human
TgeneDRD2C0422854Gustatory seizure3CTD_human
TgeneDRD2C0422855Vertiginous seizure3CTD_human
TgeneDRD2C0494475Tonic - clonic seizures3CTD_human
TgeneDRD2C0751056Non-epileptic convulsion3CTD_human
TgeneDRD2C0751088Dyskinesia, Medication-Induced3CTD_human
TgeneDRD2C0751110Single Seizure3CTD_human
TgeneDRD2C0751123Atonic Absence Seizures3CTD_human
TgeneDRD2C0751494Convulsive Seizures3CTD_human
TgeneDRD2C0751495Seizures, Focal3CTD_human
TgeneDRD2C0751496Seizures, Sensory3CTD_human
TgeneDRD2C0752097Autosomal Dominant Juvenile Parkinson Disease3CTD_human
TgeneDRD2C0752098Autosomal Dominant Parkinsonism3CTD_human
TgeneDRD2C0752100Autosomal Recessive Parkinsonism3CTD_human
TgeneDRD2C0752101Parkinsonism, Experimental3CTD_human
TgeneDRD2C0752104Familial Juvenile Parkinsonism3CTD_human
TgeneDRD2C0752105Parkinsonism, Juvenile3CTD_human
TgeneDRD2C1868675PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE JUVENILE3CTD_human
TgeneDRD2C3495874Nonepileptic Seizures3CTD_human
TgeneDRD2C4048158Convulsions3CTD_human
TgeneDRD2C4316903Absence Seizures3CTD_human
TgeneDRD2C4317109Epileptic Seizures3CTD_human
TgeneDRD2C4317123Myoclonic Seizures3CTD_human
TgeneDRD2C4505436Generalized Absence Seizures3CTD_human
TgeneDRD2C0003469Anxiety Disorders2CTD_human
TgeneDRD2C0006870Cannabis Dependence2PSYGENET
TgeneDRD2C0011206Delirium2PSYGENET
TgeneDRD2C0020514Hyperprolactinemia2CTD_human
TgeneDRD2C0024809Marijuana Abuse2PSYGENET
TgeneDRD2C0039231Tachycardia2CTD_human
TgeneDRD2C0080203Tachyarrhythmia2CTD_human
TgeneDRD2C0376280Anxiety States, Neurotic2CTD_human
TgeneDRD2C0428977Bradycardia2CTD_human
TgeneDRD2C0751217Hyperkinesia, Generalized2CTD_human
TgeneDRD2C1279420Anxiety neurosis (finding)2CTD_human
TgeneDRD2C3887506Hyperkinesia2CTD_human
TgeneDRD2C0008073Developmental Disabilities1CTD_human
TgeneDRD2C0009241Cognition Disorders1CTD_human
TgeneDRD2C0013146Drug abuse1CTD_human
TgeneDRD2C0013170Drug habituation1CTD_human
TgeneDRD2C0013222Drug Use Disorders1CTD_human
TgeneDRD2C0013384Dyskinetic syndrome1CTD_human
TgeneDRD2C0019337Heroin Dependence1CTD_human
TgeneDRD2C0020538Hypertensive disease1CTD_human
TgeneDRD2C0023015Language Disorders1CTD_human
TgeneDRD2C0024517Major depression, single episode1PSYGENET
TgeneDRD2C0025261Memory Disorders1CTD_human
TgeneDRD2C0026650Movement Disorders1CTD_human
TgeneDRD2C0028043Nicotine Dependence1CTD_human
TgeneDRD2C0029231Organic Mental Disorders, Substance-Induced1CTD_human
TgeneDRD2C0030193Pain1CTD_human
TgeneDRD2C0030567Parkinson Disease1CTD_human
TgeneDRD2C0032000Pituitary Adenoma1CTD_human
TgeneDRD2C0032019Pituitary Neoplasms1CTD_human
TgeneDRD2C0038580Substance Dependence1CTD_human
TgeneDRD2C0038586Substance Use Disorders1CTD_human
TgeneDRD2C0038587Substance Withdrawal Syndrome1CTD_human
TgeneDRD2C0040332Tobacco Dependence1CTD_human
TgeneDRD2C0041671Attention Deficit Disorder1CTD_human
TgeneDRD2C0043094Weight Gain1CTD_human
TgeneDRD2C0085996Child Development Deviations1CTD_human
TgeneDRD2C0085997Child Development Disorders, Specific1CTD_human
TgeneDRD2C0086189Drug Withdrawal Symptoms1CTD_human
TgeneDRD2C0087169Withdrawal Symptoms1CTD_human
TgeneDRD2C0152115Lingual-Facial-Buccal Dyskinesia1CTD_human
TgeneDRD2C0178417Anhedonia1PSYGENET
TgeneDRD2C0221169Hemiballismus1CTD_human
TgeneDRD2C0221480Recurrent depression1PSYGENET
TgeneDRD2C0232766Asterixis1CTD_human
TgeneDRD2C0233794Memory impairment1CTD_human
TgeneDRD2C0234230Pain, Burning1CTD_human
TgeneDRD2C0234238Ache1CTD_human
TgeneDRD2C0234254Radiating pain1CTD_human
TgeneDRD2C0236969Substance-Related Disorders1CTD_human
TgeneDRD2C0266487Etat Marbre1CTD_human
TgeneDRD2C0346300Pituitary carcinoma1CTD_human
TgeneDRD2C0376384Nicotine Use Disorder1CTD_human
TgeneDRD2C0427086Involuntary Movements1CTD_human
TgeneDRD2C0454560Acquired Language Disorders1CTD_human
TgeneDRD2C0454606Oral Dyskinesia1CTD_human
TgeneDRD2C0458257Pain, Splitting1CTD_human
TgeneDRD2C0458259Pain, Crushing1CTD_human
TgeneDRD2C0600241heroin abuse1CTD_human
TgeneDRD2C0740858Substance abuse problem1CTD_human
TgeneDRD2C0751292Age-Related Memory Disorders1CTD_human
TgeneDRD2C0751293Memory Disorder, Semantic1CTD_human
TgeneDRD2C0751294Memory Disorder, Spatial1CTD_human
TgeneDRD2C0751295Memory Loss1CTD_human
TgeneDRD2C0751407Pain, Migratory1CTD_human
TgeneDRD2C0751408Suffering, Physical1CTD_human
TgeneDRD2C0752196Ballismus1CTD_human
TgeneDRD2C1263846Attention deficit hyperactivity disorder1CTD_human
TgeneDRD2C1321905Minimal Brain Dysfunction1CTD_human
TgeneDRD2C1510472Drug Dependence1CTD_human
TgeneDRD2C4316881Prescription Drug Abuse1CTD_human
TgeneDRD2C4505390Heroin Smoking1CTD_human